174 related articles for article (PubMed ID: 32290462)
1. Long-Term Redistribution of Peripheral Lymphocyte Subpopulations after Switching from Calcineurin to mTOR Inhibitors in Kidney Transplant Recipients.
Llinàs-Mallol L; Redondo-Pachón D; Raïch-Regué D; Pérez-Sáez MJ; Yélamos J; Duran X; Faura A; López-Botet M; Pascual J; Crespo M
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32290462
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood lymphocyte subsets change after steroid withdrawal in renal allograft recipients: a prospective study.
Llinàs-Mallol L; Redondo-Pachón D; Pérez-Sáez MJ; Raïch-Regué D; Mir M; Yélamos J; López-Botet M; Pascual J; Crespo M
Sci Rep; 2019 May; 9(1):7453. PubMed ID: 31092833
[TBL] [Abstract][Full Text] [Related]
4. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients.
Crespo E; Fernandez L; Lúcia M; Melilli E; Lauzurica R; Penin RM; Quer A; Luque S; Quero M; Manonelles A; Torras J; Cruzado JM; Cañas L; Grinyó JM; Bestard O
Transplantation; 2017 Sep; 101(9):2102-2110. PubMed ID: 28403126
[TBL] [Abstract][Full Text] [Related]
5. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F
Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
[TBL] [Abstract][Full Text] [Related]
6. The Peripheral NK Cell Repertoire after Kidney Transplantation is Modulated by Different Immunosuppressive Drugs.
Neudoerfl C; Mueller BJ; Blume C; Daemen K; Stevanovic-Meyer M; Keil J; Lehner F; Haller H; Falk CS
Front Immunol; 2013; 4():46. PubMed ID: 23450662
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
Hoerning A; Wilde B; Wang J; Tebbe B; Jing L; Wang X; Jian F; Zhu J; Dolff S; Kribben A; Hoyer PF; Witzke O
Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
[TBL] [Abstract][Full Text] [Related]
8. Experience with belatacept rescue therapy in kidney transplant recipients.
Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
[TBL] [Abstract][Full Text] [Related]
9. Conversion from calcineurin inhibitors to mTOR inhibitors stabilizes diabetic and hypertensive nephropathy after liver transplant.
Álamo JM; Olivares C; Barrera L; Marín LM; Suarez G; Bernal C; Serrano J; Muntané J; Padillo FJ; Gómez MA
World J Transplant; 2015 Mar; 5(1):19-25. PubMed ID: 25815268
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin and mTOR inhibitors have opposing effects on regulatory T cells while reducing regulatory B cell populations in kidney transplant recipients.
Latorre I; Esteve-Sole A; Redondo D; Giest S; Argilaguet J; Alvarez S; Peligero C; Forstmann I; Crespo M; Pascual J; Meyerhans A
Transpl Immunol; 2016 Mar; 35():1-6. PubMed ID: 26836476
[TBL] [Abstract][Full Text] [Related]
11. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment.
Merino D; San Segundo D; Medina JM; Rodrigo E; Asensio E; Irure J; Fernández-Fresnedo G; Arias MA; López-Hoyos M
Immunology; 2016 Jun; 148(2):206-15. PubMed ID: 26931075
[TBL] [Abstract][Full Text] [Related]
12. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
Avila CL; Zimmerer JM; Elzein SM; Pham TA; Abdel-Rasoul M; Bumgardner GL
Transplantation; 2016 Sep; 100(9):1898-906. PubMed ID: 27362313
[TBL] [Abstract][Full Text] [Related]
13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors.
Ruiz San Millán JC; López-Hoyos M; Segundo DS; Quintela E; Rodrigo E; Gómez-Alamillo C; Romón I; Arias M
Transpl Int; 2014 Aug; 27(8):847-56. PubMed ID: 24707885
[TBL] [Abstract][Full Text] [Related]
15. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
16. Conversion From Calcineurin Inhibitors to Mammalian Target-of-Rapamycin Inhibitors in Heart Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials.
Qiu Y; Wang X; Fan J; Rao Z; Lu Y; Lin T
Transplant Proc; 2015 Dec; 47(10):2952-6. PubMed ID: 26707320
[TBL] [Abstract][Full Text] [Related]
17. Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review.
Olszewska B; Imko-Walczuk B; Dębska-Ślizień A
Postepy Dermatol Alergol; 2023 Apr; 40(2):187-193. PubMed ID: 37312910
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of quantitative changes in regulatory T cells in peripheral blood of kidney transplant recipients with skin cancer after conversion to mTOR inhibitors.
Cegielska A; Lisowska KA; Dębska-Ślizień A; Imko-Walczuk B; Okuniewska A; Rutkowski B
Postepy Dermatol Alergol; 2018 Oct; 35(5):474-480. PubMed ID: 30429704
[TBL] [Abstract][Full Text] [Related]
19. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
20. Effects of Conversion From Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplant Recipients.
Tsai KF; Li LC; Hsu CN; Lin CC; Lin YH; Cheng YF; Wang CC; Chen CL
J Clin Pharmacol; 2019 Mar; 59(3):326-334. PubMed ID: 30387865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
